Cancer Immunotherapy Guidelines Lymphoma Subcommittee

The disease-specific Cancer Immunotherapy Guidelines Subcommittees monitor the advancements in the cancer immunotherapy treatment options as indicated by FDA approvals of agents and companion diagnostic tools to publish and update evidence-based manuscripts for the clinical care team to utilize as a set of guidelines for treatment indications in those specific disease area. These guidelines provide key indicators to help determine when the use of immunotherapy is appropriate for cancer patient treatment.